Neurocrine Biosciences Net Change in Cash decreased by 219.8% to -$446.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1047.8%, from -$38.90M to -$446.50M. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive change indicates net cash generation, while a negative change indicates cash consumption for the period.
The total net increase or decrease in cash, cash equivalents, and restricted cash during the reporting period. It is the...
A fundamental liquidity metric used to compare cash management efficiency across all public companies.
net_change_in_cash| Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.40M | $29.70M | -$66.00M | -$106.90M | -$159.10M | $133.50M | -$42.60M | $145.20M | -$256.60M | $209.40M | -$116.10M | -$38.90M | $69.90M | $76.20M | $372.80M | -$446.50M |
| QoQ Change | — | +92.9% | -322.2% | -62.0% | -48.8% | +183.9% | -131.9% | +440.8% | -276.7% | +181.6% | -155.4% | +66.5% | +279.7% | +9.0% | +389.2% | -219.8% |
| YoY Change | — | — | — | -794.2% | -141.1% | — | — | +191.3% | — | +56.9% | -172.5% | -126.8% | +127.2% | -63.6% | +421.1% | <-999% |